-
Je něco špatně v tomto záznamu ?
How to: screening for mcr-mediated resistance to colistin
E. Smelikova, J. Tkadlec, M. Krutova
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy
- MeSH
- antibakteriální látky * farmakologie MeSH
- Bacteria * účinky léků genetika MeSH
- bakteriální léková rezistence * genetika MeSH
- kolistin * farmakologie MeSH
- mikrobiální testy citlivosti * metody MeSH
- plazmidy genetika MeSH
- polymyxiny MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
BACKGROUND: Colistin belongs to the last-resort antibiotics. The discovery of plasmid-bound colistin resistance mediated by the mcr-gene(s) is of great concern because, given its biological potential, there is a risk of its rapid spread. OBJECTIVES: To discuss the current literature on the methods for the screening for mcr-mediated resistance to colistin. SOURCES: Literature was drawn from a search of PubMed from 1 January 2016 to 26 April 2021. CONTENT: The selective culture-based or culture-independent approach can be used for the screening of mcr-mediated resistance to colistin in clinical samples. Rapid Polymyxin NP, Colistin Drop or Colistin Agar Spot tests are applicable for the selection of isolates with a suspected resistance to colistin that has to be confirmed by broth microdilution. The mcr-mediated resistance to colistin can be confirmed by the detection of the causal gene(s) or by phenotype using EDTA-colistin broth disc elution; production of the MCR-1 enzyme can be confirmed with lateral flow immunoassay, using matrix-assisted laser desorption/ionization time-of flight or liquid chromatography-based mass spectrometry. Whole-genome sequencing (WGS) is the ultimate typing method. When a WGS platform is not available at a healthcare facility, a WGS-outsourced service, in combination with freely available bioinformatics tools, allows for the characterization of the mcr-gene(s) carrying isolates. IMPLICATIONS: mcr-mediated colistin resistance should be monitored through active targeted screening. The broth microdilution method is required for colistin susceptibility testing but as only a selected number of clinical isolates are tested, colistin resistance, including mcr-mediated, may remain undetected. In mcr-1-positive Escherichia coli isolates, the MIC to colistin can range from 2 to 8 mg/L, so it is proposed that Enterobacterales with a colistin MIC of 2 mg/L should also be included in the mcr-mediated colistin resistance screening and those with a confirmed mcr-genotype and/or MCR-phenotype should be considered to be colistin-resistant.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011440
- 003
- CZ-PrNML
- 005
- 20220506125839.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cmi.2021.09.009 $2 doi
- 035 __
- $a (PubMed)34537365
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Smelikova, Eva $u Department of Medical Microbiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic
- 245 10
- $a How to: screening for mcr-mediated resistance to colistin / $c E. Smelikova, J. Tkadlec, M. Krutova
- 520 9_
- $a BACKGROUND: Colistin belongs to the last-resort antibiotics. The discovery of plasmid-bound colistin resistance mediated by the mcr-gene(s) is of great concern because, given its biological potential, there is a risk of its rapid spread. OBJECTIVES: To discuss the current literature on the methods for the screening for mcr-mediated resistance to colistin. SOURCES: Literature was drawn from a search of PubMed from 1 January 2016 to 26 April 2021. CONTENT: The selective culture-based or culture-independent approach can be used for the screening of mcr-mediated resistance to colistin in clinical samples. Rapid Polymyxin NP, Colistin Drop or Colistin Agar Spot tests are applicable for the selection of isolates with a suspected resistance to colistin that has to be confirmed by broth microdilution. The mcr-mediated resistance to colistin can be confirmed by the detection of the causal gene(s) or by phenotype using EDTA-colistin broth disc elution; production of the MCR-1 enzyme can be confirmed with lateral flow immunoassay, using matrix-assisted laser desorption/ionization time-of flight or liquid chromatography-based mass spectrometry. Whole-genome sequencing (WGS) is the ultimate typing method. When a WGS platform is not available at a healthcare facility, a WGS-outsourced service, in combination with freely available bioinformatics tools, allows for the characterization of the mcr-gene(s) carrying isolates. IMPLICATIONS: mcr-mediated colistin resistance should be monitored through active targeted screening. The broth microdilution method is required for colistin susceptibility testing but as only a selected number of clinical isolates are tested, colistin resistance, including mcr-mediated, may remain undetected. In mcr-1-positive Escherichia coli isolates, the MIC to colistin can range from 2 to 8 mg/L, so it is proposed that Enterobacterales with a colistin MIC of 2 mg/L should also be included in the mcr-mediated colistin resistance screening and those with a confirmed mcr-genotype and/or MCR-phenotype should be considered to be colistin-resistant.
- 650 12
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 12
- $a Bacteria $x účinky léků $x genetika $7 D001419
- 650 12
- $a kolistin $x farmakologie $7 D003091
- 650 12
- $a bakteriální léková rezistence $x genetika $7 D024881
- 650 12
- $a mikrobiální testy citlivosti $x metody $7 D008826
- 650 _2
- $a plazmidy $x genetika $7 D010957
- 650 _2
- $a polymyxiny $7 D011113
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Tkadlec, Jan $u Department of Medical Microbiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic
- 700 1_
- $a Krutova, Marcela $u Department of Medical Microbiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic. Electronic address: marcela.krutova@lfmotol.cuni.cz
- 773 0_
- $w MED00001139 $t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases $x 1469-0691 $g Roč. 28, č. 1 (2022), s. 43-50
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34537365 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125831 $b ABA008
- 999 __
- $a ok $b bmc $g 1789171 $s 1162638
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 28 $c 1 $d 43-50 $e 20210916 $i 1469-0691 $m Clinical microbiology and infection $n Clin Microbiol Infect $x MED00001139
- LZP __
- $a Pubmed-20220425